{"url_path":"/sec/pbsv/8-k/2026-06-15/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005989-index.html","accession_number":"0001654954-26-005989","cik":"0001304161","ticker":"PBSV","issuer_name":"Pharma-Bio Serv, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1304161/0001654954-26-005989-index.html","primary_entity_key":"0001304161","primary_entity_name":"Pharma-Bio Serv, Inc."},"word_count":88,"has_tables":true,"body_markdown":"**Item 9.01. Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n\n \n\n**Description**\n\n[99.1](pbsv_ex991.htm)\n\n \n\n[Press Release, dated June 15, 2026](pbsv_ex991.htm).\n\n104\n\n \n\nCover page Interactive Data File (embedded within the Inline XBRL document).\n\n \n\n \n\n2\n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nPHARMA-BIO SERV, INC.\n\n \n\n \n\n \n\n \n\n \n\nDate: June 15, 2026\n\nBy:\n\n/s/ Pedro J. Lasanta\n\n \n\n \n\n \n\nPedro J. Lasanta\n\n \n\n \n\n \n\nChief Financial Officer, Vice President Finance and Administration and Secretary\n\n \n\n \n\n \n\n3"}